Last reviewed 2026-04-20 · How we verify

ropivacaine 0,2%

Ropivacaine 0.2% is a marketed anesthetic agent developed by Hvidovre University Hospital, positioned in the local anesthesia market. The key composition patent expires in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of reported revenue and key trial results, which may limit investor confidence and market adoption.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery (NA)
• Enhanced Recovery After Urologic Surgery (NA)
• Regional Anesthesia Techniques in Breast Surgery (NA)
• Multimodal Analgesia Versus Peripheral Nerve Block for Postoperative Pain Management After Lower Limb Injury Surgery (NA)
• Efficacy and Safety of Liposomal Bupivacaine and Ropivacaine in Upper Limb Surgery (NA)
• The Impact of Intrathecal Morphine Versus Continuous Epidural Analgesia on Return of Bowel Function in Patients Undergoing Laparoscopic Ileal Conduit (NA)
• AoA Guided Thoracic Epidural Analgesia for Abdominal Aortic Repair (NA)
• Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.